Colorado AMC REACH Hub
Colorado AMC REACH Hub
批准号:
10475218
负责人:
RICHARD C DUKE
金额:
$98.58万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-23 至 2024-08-31
关键词:
AcademiaAdoptedAreaAutoimmunityAwardBasic ScienceBiomanufacturingBladderBotoxBusinessesCancer CenterCharacteristicsClinical ResearchClinical SciencesCollaborationsColoradoDevelopmentEcosystemEducationEnsureEntrepreneurshipEvaluation ResearchFeasibility StudiesFundingGeographyGoalsGrantHealthHealth SciencesHerpes zoster diseaseHumanHyperactivityIndustryInfrastructureInstitutesIntellectual PropertyInvestmentsKineretKnowledgeLettersMedicalMentorsMentorshipPatientsPharmaceutical PreparationsProcessProductionRegenerative MedicineResearchResearch PersonnelResource DevelopmentResource SharingResourcesScientistSpeedStructureTalentsTechnologyTechnology TransferTimeTranslatingTranslational ResearchTranslationsUnited States National Institutes of HealthUniversitiesVaccinesWorkanakinrabasecommercializationdesigneducation accessideationimprovedinnovationinquiry-based learninginvestigator traininglearning networkmyogennew technologyoperationpreventproduct developmentprogramsprototypeskill acquisitionskillssuccesstechnology developmentvalidation studies
中文摘要
摘要/摘要
本项目的目标是提高生物医学学术论文翻译的速度和成功率
发现改善人类健康的产品。为了实现这一目标,我们建议建立一个研究机构
科罗拉多大学安舒茨医学院的评估和商业化中心(科罗拉多州REACH)
校园(CU Anschutz),它将建立结合行业专业知识、指导和技能的编程
发展,以及获得资金和相关资源,以指导发明者从构思到证明
从概念研究到产品开发的早期阶段。
科罗拉多州REACH枢纽旨在实现FOA(RFA-OD-19-014)的目标,但为
利用CU Anschutz的现有资产,满足其特定需求。这所大学,有1000多名活跃人员
研究实验室,提供各种技术的强大管道和所需的科学基础设施
翻译研究。科罗拉多州REACH枢纽将建立在先前存在的类似REACH的结构之上,这些结构
纳入行业指导,依赖并提供必要的资金、教育和机会
到业务和产品开发专业知识,以弥合创新的科学想法和
集市。REACH中心有三个主要目标:(1)确定最有前途的技术并提供
为产品定义研究提供资金,(2)促进选定产品的商业化,使
技术开发资源和促进形成强大的衍生公司,以及(3)扩大
为利益相关者提供教育、体验和网络机会。
科罗拉多州REACH枢纽不仅将鼓励和促进创新,而且本身将包括创新
特点:1)创新的治理结构,将三个主要目标结合起来,避免孤岛;2)a)
以地理为重点的计划,以加快运营并最大限度地影响当地生态系统,但
建立与想法国家分享资源和经验教训的方式;3)积极主动,而不是被动地
教育方法;4)需要早期互动的有指导的技术开发资助计划
科学家、技术转移人员和行业顾问之间的合作;以及5)强调改善学术界-
通过增进相互了解、确保强大的技术和响应能力来建立行业关系
以满足行业需求。机构和地区对科罗拉多州REACH枢纽的承诺从以下方面可见一斑
配套资金和众多支持信。
英文摘要
SUMMARY/ABSTRACT
The goal of this project is to increase the speed and success rate of translating biomedical academic
discoveries into products improving human health. To achieve this, we propose establishing a research
evaluation and commercialization hub (Colorado REACH) at the University of Colorado Anschutz Medical
Campus (CU Anschutz), which will build programming that incorporates industry expertise, mentorship, skills
development, and access to funding and relevant resources to guide inventors from ideation through proof-of-
concept studies to early stages of product development.
The Colorado REACH hub is designed to fulfill the goals of the FOA (RFA-OD- 19-014), but is tailored to
leverage CU Anschutz’s existing assets and meet its specific needs. The university, with over 1000 active
research labs, provides a robust pipeline of diverse technologies and the scientific infrastructure required for
translational research. The Colorado REACH hub will build upon pre-existing REACH-like structures that
incorporate industry mentorship, and which rely on and provide the necessary funding, education, and access
to business and product development expertise to bridge the gap between innovative scientific ideas and the
marketplace. The REACH Hub has three major aims: (1) identify the most promising technologies and provide
funding for product definition studies, (2) promote commercialization of selected products, enable access to
technology development resources and facilitate formation of strong spinout companies, and (3) expand
educational, experiential, and networking opportunities for stakeholders.
The Colorado REACH hub will not only encourage and facilitate innovation, but itself will include innovative
characteristics: 1) an innovative governance structure to integrate the three main goals and avoid silos; 2) a
geographically focused program to expedite operations and maximize impact on the local ecosystem, but
building in ways to share resources and lessons learned with IDeA states; 3) a proactive, rather than passive,
approach to education; 4) a mentored technology development grant program that requires early interactions
between scientists, tech transfer staff, and industry consultants; and 5) an emphasis on improving academia-
industry relationships by increasing mutual understanding, ensuring robust technologies, and being responsive
to industry needs. Institutional and regional commitment to the Colorado REACH Hub is evident from the
matching funds and numerous letters of support.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/2211-5463.13625
发表时间:
2023-07
期刊:
FEBS open bio
影响因子:
2.6
作者:
[]
通讯作者:
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
-
批准号:10685604
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2022
-
负责人:RICHARD C DUKE
-
依托单位:
Colorado AMC REACH Hub
-
批准号:10240678
-
项目类别:
-
资助金额:$99.04万
-
财政年份:2019
-
负责人:RICHARD C DUKE
-
依托单位:
Colorado AMC REACH Hub
-
批准号:10022337
-
项目类别:
-
资助金额:$99.52万
-
财政年份:2019
-
负责人:RICHARD C DUKE
-
依托单位:
Colorado AMC REACH Hub
-
批准号:9897398
-
项目类别:
-
资助金额:$99.94万
-
财政年份:2019
-
负责人:RICHARD C DUKE
-
依托单位:
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
-
批准号:7136398
-
项目类别:
-
资助金额:$29.83万
-
财政年份:2006
-
负责人:RICHARD C DUKE
-
依托单位:
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
-
批准号:7274291
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2006
-
负责人:RICHARD C DUKE
-
依托单位:
CORE--IMMUNOLOGY
-
批准号:6300313
-
项目类别:
-
资助金额:$21.52万
-
财政年份:2000
-
负责人:RICHARD C DUKE
-
依托单位:
CORE--IMMUNOLOGY
-
批准号:6217378
-
项目类别:
-
资助金额:$21.52万
-
财政年份:1999
-
负责人:RICHARD C DUKE
-
依托单位:
CORE--IMMUNOLOGY
-
批准号:6102449
-
项目类别:
-
资助金额:$21.52万
-
财政年份:1999
-
负责人:RICHARD C DUKE
-
依托单位:
CORE--IMMUNOLOGY
-
批准号:6269337
-
项目类别:
-
资助金额:$21.36万
-
财政年份:1998
-
负责人:RICHARD C DUKE
-
依托单位:
USING LIVE, RECOMBINANT BAKERS YEAST AS AN HIV VACCINE
-
批准号:2646776
-
项目类别:
-
资助金额:$9.99万
-
财政年份:1998
-
负责人:RICHARD C DUKE
-
依托单位:
NOVEL, LIVE, RECOMBINANT YEAST BASED HIV VACCINE
-
批准号:2673202
-
项目类别:
-
资助金额:$22.14万
-
财政年份:1997
-
负责人:RICHARD C DUKE
-
依托单位:
CORE--IMMUNOLOGY
-
批准号:6236966
-
项目类别:
-
资助金额:$22.6万
-
财政年份:1997
-
负责人:RICHARD C DUKE
-
依托单位:
NOVEL, LIVE, RECOMBINANT YEAST BASED HIV VACCINE
-
批准号:2555242
-
项目类别:
-
资助金额:$22.14万
-
财政年份:1997
-
负责人:RICHARD C DUKE
-
依托单位:
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT
-
批准号:6373562
-
项目类别:
-
资助金额:$49.78万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE
-
批准号:2837474
-
项目类别:
-
资助金额:$7.3万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE
-
批准号:2607855
-
项目类别:
-
资助金额:$18.01万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT
-
批准号:6169861
-
项目类别:
-
资助金额:$49.78万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE
-
批准号:2005170
-
项目类别:
-
资助金额:$17.48万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE
-
批准号:6129518
-
项目类别:
-
资助金额:$12.01万
-
财政年份:1996
-
负责人:RICHARD C DUKE
-
依托单位:
海外基金